Exclusive Summary

• Clear Target and Unmatched Safety: Targets CD46, which is overexpressed on tumor cells, utilizing an engineered Measles Virus (MV) platform backed by 4 billion safe human vaccinations, vastly outperforming other oncolytic vectors in safety.
• Dual Mechanism Turning 'Cold' Tumors 'Hot': Employs both direct oncolytic activity and immunogenic cell death (releasing DAMP/PAMP/TAA), demonstrating in vivo efficacy superior to the current standard-of-care (Nivo+Ipi) in highly aggressive 'cold' tumors like Pleural Mesothelioma.
• FDA Orphan Drug Designation (ODD) Granted: Clinically validated unmet need with an existing FDA ODD for Pleural Mesothelioma, ensuring expedited development curves and significant regulatory de-risking for potential partners.
• Disruptive Low Efficacious Dose & Stability: Thanks to a proprietary virulence factor C deletion (ΔC), it requires exponentially lower dosages (10^6-10^7 PFU vs. 10^8-10^12 for standard viral vectors), drastically reducing CMC hurdles and manufacturing costs.
• Massive Out-Licensing Potential & AI Synergy: Features a high-value 'orphan-to-blockbuster' expansion strategy, significantly bolstered by a US-based AI digital cell cloning partnership, making it an ideal combination partner for MNCs looking to revitalize their Immune Checkpoint Inhibitor (ICI) franchises.

Asset Materials

Contact Us for Full Materials